Emergent BioSolutions (EBS) Assets Average (2011 - 2026)

Emergent BioSolutions' Assets Average history runs 16 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 6.28% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 6.28% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 15.71% from the prior year.
• Assets Average retreated to $1.3 billion in Q1 2026 per EBS's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $3.1 billion in Q1 2023 and bottomed at $1.3 billion in Q1 2026.
• The 5-year median for Assets Average is $1.8 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Assets Average increased 6.59% in 2023 and plunged 40.7% in 2024, its largest moves.
• Year by year, Assets Average stood at $3.0 billion in 2022, then plunged by 38.7% to $1.9 billion in 2023, then dropped by 22.84% to $1.4 billion in 2024, then decreased by 3.07% to $1.4 billion in 2025, then decreased by 5.06% to $1.3 billion in 2026.
• Per Business Quant, the three latest EBS Assets Average figures stand at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025).